Tag Archive for: numab

Weekly Roundup: One week till Optimum’s Annual Healthcare Investor Conference

/in

Sofinnova Partners closed oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand […]

Read more

Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

/in

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using […]

Read more
© Optimum Strategic Communications.